Will COVID-19 spur disruptive innovation in vaccine studies? The current pandemic has put a bright spotlight on vaccine trials, showing why it’s never been more urgent for robust and thoughtful vaccine trial designs that can be executed efficiently and nimbly. Typically shorter in duration relative to other trials, vaccine trials can cause an increased pressure to plan and execute adeptly.
Join VP, Strategic Development, Scott Treiber, along with AMR’s Chief Medical Officer, Dr Jeffrey Rosen, on Tuesday June 30th, 2020 for an upcoming webinar titled ‘Addressing the Rapidly Evolving Vaccine Development Landscape.’ Optimal approaches to study design and execution, with acknowledgement of the specific challenges presented by different trials and disease states, will be explored.
Treiber and Rosen will address current best practices that enhance vaccine trials performance, such as including experienced sites in protocol development and how to focus site selection to maximize patient numbers across fewer sites for reduced variability. They will detail operational guidance like abbreviate ICFs for rapid pre-screening, pre-emptive measures to accelerate enrollment and operational efficiencies that can improve the speed and quality of vaccine trials. Historical case studies (Zika, Dengue, Chikungunya) will be discussed to demonstrate how these changed the approach to subsequent trials.
Each trial presents its own specific challenges. How will the current pandemic inform, adapt, or completely alter some of these proven strategies? Current events put into sharper focus the need for streamlined, accessible technologies that can make vaccine trials quicker, easier and more patient-centric.
Can tools such as ePRO diaries, telemedicine, HIPAA-compliant virtual systems and more aid in delivering results faster while maintaining quality? The presenters will explore these topics and provide practical insights on how vaccine trial planning and execution can evolve moving forward.
Scott Treiber, PhD, MBA, Vice President, Strategic Development, Synteract
Dr Scott Treiber is a CRO industry veteran with 28 years of clinical development experience. Most recently, Dr Treiber was Chief Operating Officer at Elligo Health Research. Before that, he was Executive Vice President, Biopharmaceutical Development and GM at Chiltern. Dr Treiber has expertise in clinical operations, clinical development, medical affairs, data management/statistics, pharmacovigilance/safety and quality. He has broad therapeutic expertise in neuroscience, oncology, infectious disease, pain, gastroenterology, respiratory and women’s health. Dr Treiber has a BA in biology from the University of Iowa, a PhD in neuroscience from the University of California Santa Cruz and an MBA from New York Institute of Technology.Message Presenter
Jeffrey Rosen, MD, Chief Medical Officer, Alliance of MultiSpecialty Research (AMR)
Dr Jeffrey Rosen is the Medical Director of Clinical Research of South Florida. He has been conducting clinical research for 34 years and has been involved in more than 800 clinical trials. Dr Rosen is a founding member of AMR and is on the Leadership Council for the Society for Clinical Research Sites. He has been a speaker at many research conferences and for several pharmaceutical companies.Message Presenter
Who Should Attend?
This webinar will appeal to VPs, Directors, Managers, Department Heads, Scientists and Researchers working within:
- Clinical Affairs
- Clinical R&D
- Clinical Research
- Clinical Pharmacology
- Clinical Operations
- Project Management
- Regulatory Affairs
- Medical Affairs
What You Will Learn
At the conclusion of this webinar, attendees will have learned:
- Keys to proactively approaching your vaccine trial
- Key operational takeaways for vaccine trials that you can use today
- How to be ahead of the curve and prepare now for the next generation of vaccine trials
With employees across 21 countries, Synteract is an innovative, full-service CRO supporting biopharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and 750,000 patients. Greater than 245 of its 4,000 studies have been in pediatric populations. In addition to pediatrics clinical trials, Synteract offers a notable depth of therapeutic expertise in dermatology, neurodegenerative, oncology and immunotherapy, and rare/orphan disease studies.